WebConformational changes in human prolyl-tRNA synthetase upon binding of the substrates proline and ATP and the inhibitor halofuginone Aminoacyl-tRNA synthetases recognize cognate amino acids and tRNAs from their noncognate counterparts and catalyze the formation of aminoacyl-tRNAs. WebSep 1, 2024 · Halofuginone is an important aaRSs inhibitor. 19., 20. A well-established mechanism of halofuginone is the inhibition of prolyl-tRNA synthetase (PRS): direct binding of halofuginone to PRS and consequent inhibition of PRS has been reported ( Fig. 2 ). 19., 20.
Prolyl-tRNA synthetase as a novel therapeutic target in …
WebHalofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. WebMar 12, 2024 · The polyketide natural product reveromycin A (RM-A) exhibits antifungal, anticancer, anti-bone metastasis, anti-periodontitis and anti-osteoporosis activities by selectively inhibiting eukaryotic... the bay kelowna
Conformational changes in human prolyl-tRNA synthetase upon
WebBersiporocin is a prolyl-tRNA synthetase inhibitor. Bersiporocin has an IC50 of ≤100 nM for phosphoribosylpyrophosphate synthetase (PRS). Bersiporocin can be used for the research of antifibrotic. For research use only. We do not sell to patients. Bersiporocin Chemical Structure CAS No. : 2241808-52-4 * Please select Quantity before adding items. WebMar 26, 2024 · Summary Paragraph We identify the prolyl-tRNA synthetase (PRS) inhibitor halofuginone 1, a compound in clinical trials for anti-fibrotic and anti-inflammatory applications 2, as a potent inhibitor of SARS-CoV-2 infection and replication. The interaction of SARS-CoV-2 spike protein with cell surface heparan sulfate (HS) promotes viral entry 3. WebGEO help: Mouse over screen elements for information. Scope: Format: Amount: GEO accession: Series GSE186447. Query DataSets for GSE186447. Status. Public on Sep 08, 2024. Title. NCP26 is a potent prolyl-tRNA synthetase inhibitor and induces pro- apoptotic responses with in vivo potency in multiple myeloma. Single-cell RNA-seq data BM samples. the harpur trust companies house